TABLE III.
HIV-1 Drug-Resistance Mutations by Viral Subtype (CRF02_AG vs. Non-CRF02_AG) Among HAART-Experienced Individuals
| Cameroon1 | Stanford University HIV Drug-Resistance DB2 | |||
|---|---|---|---|---|
| ARV class | Mutation | CRF02_AG (%), n = 24 | Non-CRF02_AG (%), n = 4 | CRF02_AG (%), n = 139 |
| NRTI | A62V | 1 (4) | 1 (25) | 1 (1) |
| K65R | 1 (4) | 0 (0) | 4 (3) | |
| V75I | 0 (0) | 1 (25) | 2 (1) | |
| F77L | 0 (0) | 1 (25) | 1 (1) | |
| F116Y | 2 (8) | 0 (0) | 2 (1) | |
| Q151M | 2 (8) | 1 (17) | 3 (2) | |
| M184V | 8 (33) | 3 (75) | 42 (30) | |
| T215Y | 3 (13) | 0 (0) | 10 (7) | |
| NNRTI | K103NS | 4 (17) | 1 (0) | 40 (29) |
| V106A | 1 (4) | 1 (25) | 2 (1) | |
| V108I | 2 (8) | 0 (0) | 6 (4) | |
| V179E | 2 (8) | 0 (0) | 3 (2) | |
| Y181C | 4 (17) | 1 (25) | 10 (7) | |
| Y188L | 0 (0) | 1 (25) | 5 (4) | |
| G190A | 3 (13) | 0 (0) | 4 (3) | |
| F227L | 2 (8) | 1 (25) | 1 (1) | |
The number and percentage of RTI-resistance mutations based on the analysis of
1
28 HAART-experienced individuals from Cameroon infected with RT subtype CRF02_AG or non-CRF02_AG (D or CRF11_cpx) were compared to
2
CRF02_AG-infected individuals on a HAART of two NRTIs and one NNRTI that were compiled using the “literature prevalence of mutations in submitted sequences” of the HIVseq program available at the Stanford University HIV Drug-Resistance Database website.